Paramagnetic rim lesions (PRLs) are chronic active lesions associated with a more severe disease course in multiple sclerosis (MS). Retinal layer thinning measured by optical coherence tomography (OCT) is a biomarker of neuroaxonal damage associated with disability progression in MS.
Objective:
We aimed to determine a potential association between OCT parameters (peripapillary retinal nerve fiber layer (pRNFL) ganglion cell-inner plexiform layer (GCIPL), inner nuclear layer (INL) thickness), and PRLs in patients with MS (pwMS).
Methods:
In this cross-sectional retrospective study, we included pwMS with both 3T brain MRI and an OCT scan. Regression models were calculated with OCT parameters (pRNFL, GCIPL, INL) as dependent variables, and the number of PRLs as an independent variable adjusted for covariates.
Results:
We analyzed data from 107 pwMS (mean age 34.7 years (SD 10.9), 64.5% female, median disease duration 6 years (IQR 1–13), median EDSS 1.5 (range 0–6.5)). Higher number of PRLs was associated with lower pRNFL (β = −0.18; 95% CI −0.98, −0.03; p = 0.038) and GCIPL thickness (β = −0.21; 95% CI −0.58, −0.02; p = 0.039).
Conclusion:
The association between higher number of PRLs and lower pRNFL and GCIPL thicknesses provides additional evidence that pwMS with PRLs are affected by a more pronounced neurodegenerative process.
Dal-BiancoAGrabnerGKronnerwetterC, et al. Slow expansion of multiple sclerosis iron rim lesions: Pathology and 7 T magnetic resonance imaging. Acta Neuropathol2017; 133(1): 25–42.
2.
KaunznerUWKangYZhangS, et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain2019; 142(1): 133–145.
3.
AlTokhisAIAlOtaibiAMFelmbanGA, et al. Iron rims as an imaging biomarker in MS: A systematic mapping review. Diagnostics2020; 10(11): 968.
4.
AbsintaMDal—BiancoA.Slowly expanding lesions are a marker of progressive MS—Yes. Mult Scler2021; 27(11): 1679–1681.
5.
Dal-BiancoAGrabnerGKronnerwetterC, et al. Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI. Brain2021; 144(3): 833–847.
6.
AbsintaMSatiPSchindlerM, et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest2016; 126(7): 2597–2609.
7.
HuHYeLDingS, et al. The heterogeneity of tissue destruction between iron rim lesions and non-iron rim lesions in multiple sclerosis: A diffusion MRI study. Mult Scler Relat Disord2022; 66: 104070.
8.
BritzeJFrederiksenJL.Optical coherence tomography in multiple sclerosis. Eye2018; 32(5): 884–888.
9.
SaidhaSSotirchosESOhJ, et al. Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol2013; 70(1): 34–43.
10.
BstehGBerekKHegenH, et al. Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis. Mult Scler2021; 27(5): 684–694.
11.
BstehGHegenHTeuchnerB, et al. Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. Mult Scler2019; 25(2): 196–203.
12.
SchurzNSariaslaniLAltmannP, et al. Evaluation of retinal layer thickness parameters as biomarkers in a real-world multiple sclerosis cohort. Eye Brain2021; 13: 59–69.
13.
BalkLJCoricDKnierB, et al. Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. Mult Scler J Exp Transl Clin2019; 5(3): 9871582.
14.
BstehGHegenHAltmannP, et al. Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis. Mult Scler J Exp Transl Clin2020; 6(3): 0945738.
15.
KnierBSchmidtPAlyL, et al. Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. Brain2016; 139(11): 2855–2863.
16.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
17.
BstehGHegenHRiedlK, et al. Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score. Eur J Neurol2021; 28(5): 1609–1616.
18.
KurtzkeJF.Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology1983; 33(11): 1444–1452.
19.
PoserCMPatyDWScheinbergL, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol1983; 13(3): 227–231.
20.
PempBKardonRHKircherK, et al. Effectiveness of averaging strategies to reduce variance in retinal nerve fibre layer thickness measurements using spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol2013; 251(7): 1841–1848.
21.
Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology1991; 98(Suppl. 5): 807–822.
22.
TewariePBalkLCostelloF, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE2012; 7(4): e34823.
23.
Nolan-KenneyRCLiuMAkhandO, et al. Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. Ann Neurol2019; 85(5): 618–629.
24.
BstehGHegenHAltmannP, et al. Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis. Mult Scler Relat Disord2020; 45: 102403.
25.
SaidhaSAl-LouziORatchfordJN, et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study. Ann Neurol2015; 78(5): 801–813.
26.
AytulunACruz-HerranzAAktasO, et al. APOSTEL 2.0 recommendations for reporting quantitative optical coherence tomography studies. Neurology2021; 97(2): 68–79.
27.
FilippiMPreziosaPBanwellBL, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: Practical guidelines. Brain2019; 142(7): 1858–1875.
28.
AbsintaMSatiPMasuzzoF, et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol2019; 76(12): 1474–1483.
29.
KornekBStorchMKWeissertR, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol2000; 157(1): 267–276.
30.
BramowSFrischerJMLassmannH, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain2010; 133(10): 2983–2998.
31.
Dal-BiancoASchranzerRGrabnerG, et al. Iron rims in patients with multiple sclerosis as neurodegenerative marker? A 7-Tesla magnetic resonance study. Front Neurol2021; 12: 632749.
32.
MaggiPKuhleJSchädelinS, et al. Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis. Neurology2021; 97(6): e543–e553.
33.
WeberCEKramerJWittayerM, et al. Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis. Eur Radiol2022; 32(3): 2012–2022.
34.
WenzelNWittayerMWeberCE, et al. MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions. J Neurol2022; 269(8): 4414–4420.
35.
KrajncNBstehGKasprianG, et al. Peripheral hemolysis in relation to iron rim presence and brain volume in multiple sclerosis. Front Neurol2022; 13: 928582.
36.
HemondCCBaekJIoneteC, et al. Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study. Mult Scler2022; 28(13): 2046–2056.
37.
DinkinM.Trans-synaptic retrograde degeneration in the human visual system: Slow, silent, and real. Curr Neurol Neurosci Rep2017; 17(2): 16.
38.
BstehGHegenHAltmannP, et al. Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis. Eur J Neurol2021; 28(6): 2037–2045.
39.
RatchfordJNSaidhaSSotirchosES, et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology2013; 80(1): 47–54.
40.
KnierBBertheleABuckD, et al. Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelination. Mult Scler2016; 22(7): 893–900.
